Literature DB >> 6401600

Enhanced incorporation of radioactive inorganic phosphate into phospholipids of HeLa cells by tumor promoters.

H Nishino, H Fujiki, M Terada, S Sato.   

Abstract

Teleocidin, a new tumor promoter, increased incorporation of radioactive inorganic phosphate (32Pi) into phospholipids in HeLa cells. This effect was detected within 1 h on incubation of the cells in medium containing teleocidin. The half-maximum effective dose of teleocidin was approximately 10 ng/ml. The main effect of teleocidin was on the incorporation of 32Pi into the phosphatidylcholine fraction, with a lesser effect on 32Pi incorporation into other phospholipid fractions. Increased incorporation of 32Pi into phospholipids was also observed on incubation of the cells with 12-O-tetradecanoylphorbol-13-acetate (TPA), dihydroteleocidin B, or lyngbyatoxin A, which are all complete tumor promoters, and also with mezerein, which is an incomplete and second stage promoter. On the other hand, at concentrations of up to 1 microgram/ml, 4-O-methyl TPA and Ca2+ ionophore A23187, which are incomplete and first stage promoters, and phorbol, which has no promoting activity in skin carcinogenesis, did not cause any increased incorporation of 32Pi into phospholipid fractions of HeLa cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6401600     DOI: 10.1093/carcin/4.1.107

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  2 in total

1.  Effects of the phorbolester TPA and of the ionophore A 23187 on phospholipase A2 and C activities in the mouse epidermal cell line HEL-30.

Authors:  G Fürstenberger; M Rogers; J Faberman; M Ganss; H Richter; F Marks
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

2.  A two-stage mouse skin carcinogenesis study of lyngbyatoxin A.

Authors:  H Fujiki; M Suganuma; H Hakii; G Bartolini; R E Moore; S Takayama; T Sugimura
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.